334 Shares in Icon Plc $ICLR Purchased by LRI Investments LLC

LRI Investments LLC bought a new position in shares of Icon Plc (NASDAQ:ICLR) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 334 shares of the medical research company’s stock, valued at approximately $49,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Inspire Investing LLC lifted its holdings in shares of Icon by 42.2% during the second quarter. Inspire Investing LLC now owns 14,691 shares of the medical research company’s stock worth $2,137,000 after purchasing an additional 4,362 shares during the period. Aberdeen Group plc lifted its holdings in Icon by 5.6% in the second quarter. Aberdeen Group plc now owns 59,211 shares of the medical research company’s stock valued at $8,612,000 after acquiring an additional 3,165 shares during the period. Blue Trust Inc. lifted its holdings in Icon by 44.0% in the second quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock valued at $57,000 after acquiring an additional 120 shares during the period. Hunter Perkins Capital Management LLC lifted its holdings in Icon by 0.4% in the second quarter. Hunter Perkins Capital Management LLC now owns 22,399 shares of the medical research company’s stock valued at $3,258,000 after acquiring an additional 97 shares during the period. Finally, Sendero Wealth Management LLC acquired a new position in Icon in the second quarter valued at approximately $2,415,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Stock Up 1.4%

Shares of ICLR opened at $186.05 on Tuesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.29 and a current ratio of 1.29. Icon Plc has a one year low of $125.10 and a one year high of $301.45. The stock has a market capitalization of $15.03 billion, a price-to-earnings ratio of 19.14, a PEG ratio of 2.72 and a beta of 1.23. The stock has a 50 day moving average price of $174.99 and a 200 day moving average price of $156.75.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $3.26 EPS for the quarter, topping the consensus estimate of $3.18 by $0.08. The firm had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $1.98 billion. Icon had a return on equity of 10.95% and a net margin of 9.82%.The firm’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same period in the previous year, the business earned $3.75 earnings per share. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. Equities research analysts forecast that Icon Plc will post 13.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Rothschild & Co Redburn raised Icon from a “neutral” rating to a “buy” rating and boosted their price target for the company from $184.00 to $236.00 in a report on Wednesday, September 3rd. Jefferies Financial Group downgraded Icon from a “buy” rating to a “hold” rating and decreased their price target for the company from $220.00 to $175.00 in a report on Tuesday, September 9th. Barclays boosted their price target on Icon from $180.00 to $190.00 and gave the company an “equal weight” rating in a report on Thursday, October 2nd. Rothschild Redb raised Icon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Icon in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $210.64.

Icon Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.